Search

Scottsdale Healthcare Video Library

Tags

active affiliate affiliation agree allred alvin angel animation anniversary announce aortic arcadia are aryana attack awareness back bariatric beckman benefit between bill blackstone blood burke cancer cardiac care center choice christopher cibulka clifford clinical colon community coordinator coronary cruickshank daniel davinci debbie dee demo denis desiderio difference disease dissolving doctors eric exercise families fearless featuring fine finlay flow frank function galleria game gazda glennie goldberg gomez gown graff green groove gustin hands hawthorne healing health healthcare heart hearts heather hoff hospital hospitals hughes hybrid hyperbaric imaging immunizations important inoperable institute investigational james jamie jason jeffrey jennifer john june karen kelly kids knee learning leitner lewis lincoln lipiscan little lou lowery magnet makoplasty mario mark mary matthews medical medical reconciliation training meet mesa michael military minute miracle miracles mission mitch mitchell more mri naghipour nahid nathan network nick nicu orthopedic osborn oxygen paradise participates partnership patient peak philanthropy pictures piper preparing primary procedure prostate recovery research restores reunion reynoso risk robert robin robot saddle schmidt scottsdale segal shea slater stacy stand stat stenosis stent story study success supports surgery surgical swain system tanara tavr tempe testimonial testimonials therapy thompson thunder tracy training trauma treatment trials usaf valley vascular video virginia von webster white women wong years
Investigational cancer treatment study
Investigational cancer treatment study
A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. TKM-PLK-1 targets a protein called polo-like kinase 1 (PLK1) that promotes tumor cell reproduction. It prevents the tumor from completing cell division, resulting in death of the cancer cell. The Virginia G. Piper Cancer Center at Scottsdale Healthcare will be among the first in the world to study the treatment in humans. The new drug is being developed as a treatment for patients with advanced solid tumor cancers who are not well served by current therapy. The Phase 1 clinical trial will evaluate the safety, tolerability and how the body metabolizes TKM-PLK1. Laboratory research showed the investigational compound may have effectiveness in treating colorectal, breast, non-small cell lung, and ovarian cancers. These diseases collectively affect more than 500,000 new patients each year in the United States. Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339, toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org. For more information about Virginia G. Piper Cancer Center Clinial Trials, visit http://www.shc.org/clinicaltrials.